CHAUNCE RUFF: Open Payments
NPI 1225113186 · RICHLAND, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,582 in 71 payments from 17 companies in 2025. Trend: 2023 $994 · 2024 $1,446 · 2025 $1,582
Food & beverage: $1,582
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 13 | $351 |
| ABBVIE INC. | 15 | $331 |
| PFIZER INC. | 11 | $163 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $136 |
| GlaxoSmithKline, LLC. | 6 | $114 |
| Abbott Laboratories | 1 | $80 |
| Lilly USA, LLC | 3 | $65 |
| Novo Nordisk Inc | 3 | $63 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $51 |
Products named: UBRELVY, Kerendia, FARXIGA, ELIQUIS, QULIPTA, FREESTYLE LIBRE 3, SHINGRIX, REXULTI.
Industry payments across WA — which companies pay providers there.
